Search peptides, terms, sources/
Regulatory source · 2012

Egrifta (tesamorelin), EPAR, Withdrawal of marketing-authorisation application

About this source

Kind
Regulatory or official document
Population
Not applicable (regulatory assessment); underlying trial population per the pivotal NEJM trial
Primary or secondary
primary
Peer review
unknown
Retraction status
None known
Date checked
14 August 2026

Limitations

The application was withdrawn by the applicant before a final CHMP opinion was reached, a provisional/preliminary CHMP assessment (data did not allow the Committee to conclude on a positive benefit-risk balance), not a formal refusal.

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.